Biotech Values

[DewDiligence]

AGTC files IND for lead program in X-linked retinoschisis:

http://finance.yahoo.com/news/agtc-files-investigational-drug-application-110000179.html

Pending the FDA's acceptance of the IND application, the Company plans to initiate a clinical study evaluating the safety and efficacy of AGTC's proprietary gene therapy for treating XLRS during the second quarter of 2015 and expects to have initial data during the second half of 2015.

XLRS is an inherited retinal disease caused by mutations in the RS1 gene, which encodes the retinoschisin protein. XLRS is characterized by abnormal splitting of the layers of the retina, resulting in poor visual acuity in young boys, which can worsen as the patients age. There are currently no approved treatments for XLRS.

AGTC is presenting at the Roth conference today at 1:30pm ET.